Henry Schein (HSIC) Research | Aerarium Research

Forward Estimates

EPS Estimates

Current Qtr

$1.23

$1.12$1.37

vs $1.10+11.9%

15 analysts

Next Qtr

$1.37

$1.29$1.46

vs $1.38-0.6%

15 analysts

Current Yr

$5.34

$5.25$5.43

vs $4.97+7.5%

16 analysts

Next Yr

$5.91

$5.74$6.24

vs $5.34+10.5%

16 analysts

Revenue Estimates

Current Qtr

$3.38B

$3.35B$3.41B

vs $3.24B+4.2%

13 analysts

Next Qtr

$3.46B

$3.43B$3.51B

vs $3.34B+3.5%

13 analysts

Current Yr

$13.75B

$13.70B$13.90B

vs $13.18B+4.3%

15 analysts

Next Yr

$14.26B

$14.12B$14.44B

vs $13.75B+3.8%

15 analysts

SEC filings →

View all 10-K, 10-Q, and 8-K filings for HSIC on EDGAR.

HSIC filing events and research context
Filed	Item	Context
Feb 24, 2026	business	Henry Schein, Inc. is a global distributor of healthcare products and value-added services, primarily serving office-based dental and medical practitioners. The company operates through three reportable segments: Global Distribution and Value-Added Services, which provides dental merchandise, equipment, and medical supplies; Global Specialty Products, focusing on the manufacture of dental implants and orthopedic products; and Global Technology, which develops practice management software and cloud-based platforms. For the fiscal year 2025, the company reported net sales of $13.18 billion, with growth driven by the adoption of cloud-based technology and expansion in home solutions. Under its BOLD+1 strategic plan, the company is executing a restructuring program through 2027 to integrate acquisitions and improve operational efficiency. Key financial risks include exposure to foreign currency fluctuations and interest rate volatility, managed via forward contracts and swaps. The company is also managing the residual impacts of a 2023 cyber incident and potential tax liabilities arising from the OECD Pillar Two global minimum tax rules. Growth is sustained through a targeted acquisition strategy focusing on high-margin businesses and expansion into emerging markets to increase geographic footprint and technological capabilities.
Feb 24, 2026	mda	Henry Schein, Inc. reported 2025 net sales of $13.18 billion, a 4.0% increase driven by growth in Global Technology (7.1%) and Global Specialty Products (6.7%), specifically cloud-based practice management software, implants, and biomaterials. Net income rose to $419 million, though net cash from operating activities decreased to $712 million as cash collections normalized following an October 2023 cyber incident. The company is executing a restructuring plan through 2027 to integrate acquisitions and right-size operations, incurring $105 million in related charges in 2025. Strategic developments include a January 2025 partnership with KKR Hawaii Aggregator L.P. and the appointment of Frederick M. Lowery as CEO, effective March 2026. Financial headwinds include the One Big Beautiful Bill Act, which is expected to reduce Medicaid enrollment and federal funding, potentially lowering product utilization. Additionally, while tariffs had a limited overall impact in 2025, they caused temporary volatility in U.S. dental equipment sales. Long-term growth is supported by an aging population and the consolidation of healthcare providers into Dental Support Organizations (DSOs) and Group Purchasing Organizations (GPOs).
Feb 24, 2026	risk_factors	Henry Schein faces significant operational risks stemming from its dependence on third-party manufacturers and suppliers for raw materials and product assembly. Strategic uncertainties center on the execution of its 2024 restructuring plan and the January 2025 Strategic Partnership Agreement with KKR Hawaii Aggregator L.P. The company is navigating a critical leadership transition as Frederick M. Lowery succeeds Stanley M. Bergman as CEO in March 2026. Financial performance remains sensitive to cybersecurity threats, evidenced by the October 2023 incident that reduced sales within North American and European dental and medical distribution. Market pressures include consolidation via Dental Service Organizations (DSOs) and Group Purchasing Organizations (GPOs), alongside competition from online commerce. Regulatory headwinds include the EU Medical Device Regulation and the One Big Beautiful Bill Act (OBBBA), the latter of which is expected to decrease Medicaid enrollment and federal funding, adversely impacting product utilization. Additionally, the company is exposed to volatile global trade conditions, including U.S. tariffs and geopolitical instability in Ukraine and the Middle East. Maintaining margins for specialty products, such as implants and biomaterials, and practice management software is essential amid these macroeconomic and regulatory shifts.

Filed

Item

Context

Feb 24, 2026

business

Henry Schein, Inc. is a global distributor of healthcare products and value-added services, primarily serving office-based dental and medical practitioners. The company operates through three reportable segments: Global Distribution and Value-Added Services, which provides dental merchandise, equipment, and medical supplies; Global Specialty Products, focusing on the manufacture of dental implants and orthopedic products; and Global Technology, which develops practice management software and cloud-based platforms. For the fiscal year 2025, the company reported net sales of $13.18 billion, with growth driven by the adoption of cloud-based technology and expansion in home solutions. Under its BOLD+1 strategic plan, the company is executing a restructuring program through 2027 to integrate acquisitions and improve operational efficiency. Key financial risks include exposure to foreign currency fluctuations and interest rate volatility, managed via forward contracts and swaps. The company is also managing the residual impacts of a 2023 cyber incident and potential tax liabilities arising from the OECD Pillar Two global minimum tax rules. Growth is sustained through a targeted acquisition strategy focusing on high-margin businesses and expansion into emerging markets to increase geographic footprint and technological capabilities.

Feb 24, 2026

mda

Henry Schein, Inc. reported 2025 net sales of $13.18 billion, a 4.0% increase driven by growth in Global Technology (7.1%) and Global Specialty Products (6.7%), specifically cloud-based practice management software, implants, and biomaterials. Net income rose to $419 million, though net cash from operating activities decreased to $712 million as cash collections normalized following an October 2023 cyber incident. The company is executing a restructuring plan through 2027 to integrate acquisitions and right-size operations, incurring $105 million in related charges in 2025. Strategic developments include a January 2025 partnership with KKR Hawaii Aggregator L.P. and the appointment of Frederick M. Lowery as CEO, effective March 2026. Financial headwinds include the One Big Beautiful Bill Act, which is expected to reduce Medicaid enrollment and federal funding, potentially lowering product utilization. Additionally, while tariffs had a limited overall impact in 2025, they caused temporary volatility in U.S. dental equipment sales. Long-term growth is supported by an aging population and the consolidation of healthcare providers into Dental Support Organizations (DSOs) and Group Purchasing Organizations (GPOs).

Feb 24, 2026

risk_factors

Henry Schein faces significant operational risks stemming from its dependence on third-party manufacturers and suppliers for raw materials and product assembly. Strategic uncertainties center on the execution of its 2024 restructuring plan and the January 2025 Strategic Partnership Agreement with KKR Hawaii Aggregator L.P. The company is navigating a critical leadership transition as Frederick M. Lowery succeeds Stanley M. Bergman as CEO in March 2026. Financial performance remains sensitive to cybersecurity threats, evidenced by the October 2023 incident that reduced sales within North American and European dental and medical distribution. Market pressures include consolidation via Dental Service Organizations (DSOs) and Group Purchasing Organizations (GPOs), alongside competition from online commerce. Regulatory headwinds include the EU Medical Device Regulation and the One Big Beautiful Bill Act (OBBBA), the latter of which is expected to decrease Medicaid enrollment and federal funding, adversely impacting product utilization. Additionally, the company is exposed to volatile global trade conditions, including U.S. tariffs and geopolitical instability in Ukraine and the Middle East. Maintaining margins for specialty products, such as implants and biomaterials, and practice management software is essential amid these macroeconomic and regulatory shifts.

Forward Estimates

HSIC filing events and research context

Keep researching HSIC

Related tickers

Related explainers

Forward Estimates